[go: up one dir, main page]

Risacher et al., 2017 - Google Patents

Olfactory identification in subjective cognitive decline and mild cognitive impairment: association with tau but not amyloid positron emission tomography

Risacher et al., 2017

View HTML @Full View
Document ID
2549155643401788531
Author
Risacher S
Tallman E
West J
Yoder K
Hutchins G
Fletcher J
Gao S
Kareken D
Farlow M
Apostolova L
Saykin A
Publication year
Publication venue
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring

External Links

Snippet

Introduction We investigated the association between olfactory identification and Alzheimer's disease biomarkers, including amyloid, tau, and neurodegeneration. Methods Thirty-four older adults, including 19 cognitively normal (CN), 10 subjective cognitive decline (SCD) …
Continue reading at www.sciencedirect.com (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital

Similar Documents

Publication Publication Date Title
Risacher et al. Olfactory identification in subjective cognitive decline and mild cognitive impairment: association with tau but not amyloid positron emission tomography
Mecca et al. In vivo measurement of widespread synaptic loss in Alzheimer's disease with SV2A PET
O’Dell et al. Association of Aβ deposition and regional synaptic density in early Alzheimer’s disease: a PET imaging study with [11C] UCB-J
Ossenkoppele et al. Longitudinal imaging of Alzheimer pathology using [11C] PIB,[18F] FDDNP and [18F] FDG PET
Pascoal et al. Aβ-induced vulnerability propagates via the brain’s default mode network
Pontecorvo et al. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition
van Assema et al. P-glycoprotein function at the blood–brain barrier: effects of age and gender
Cerami et al. Brain metabolic maps in Mild Cognitive Impairment predict heterogeneity of progression to dementia
Wu et al. Increased brain amyloid deposition in patients with a lifetime history of major depression: evidenced on 18F-florbetapir (AV-45/Amyvid) positron emission tomography
Madsen et al. Lack of association between prior depressive episodes and cerebral [11C] PiB binding
Chiaravalloti et al. Comparison between early-onset and late-onset Alzheimer's disease patients with amnestic presentation: CSF and 18F-FDG PET study
Filippi et al. EFNS guidelines on the use of neuroimaging in the management of motor neuron diseases
Risacher et al. Visual contrast sensitivity is associated with the presence of cerebral amyloid and tau deposition
Kamagata et al. Posterior hypoperfusion in Parkinson's disease with and without dementia measured with arterial spin labeling MRI
Mohamed et al. Traumatic brain injury fast-forwards Alzheimer’s pathology: evidence from amyloid positron emission tomorgraphy imaging
Lee et al. [18F]-THK5351 PET imaging in patients with semantic variant primary progressive aphasia
Sanjari Moghaddam et al. Association of olfaction dysfunction with brain microstructure in prodromal Parkinson disease
Hayek et al. Different inflammatory signatures based on CSF biomarkers relate to preserved or diminished brain structure and cognition
Lam et al. White matter hyperintensities and cognition across different Alzheimer's biomarker profiles
Förster et al. Effects of a 6-month cognitive intervention on brain metabolism in patients with amnestic MCI and mild Alzheimer's disease
Ferraro et al. Perfusion alterations converge with patterns of pathological spread in transactive response DNA-binding protein 43 proteinopathies
Pradhan et al. Serum FOXO3A: A ray of hope for early diagnosis of Alzheimer’s disease
Liu et al. FDG-PET assessment of the locus coeruleus in Alzheimer’s disease
Teipel et al. Association of CSF sTREM2, a marker of microglia activation, with cholinergic basal forebrain volume in major depressive disorder
Lee et al. Effects of Alzheimer and Lewy body disease pathologies on brain metabolism